Alvotech (ALVO) and Teva Pharmaceutical (TEVA) said Monday that the US Food and Drug Administration has accepted to review their biologics license applications for AVT05 to treat inflammatory conditions.
The review process is expected to be completed in Q4.
This comes after the achievement of positive top-line results in April 2024 from a confirmatory clinical study comparing AVT05 with biosimilar Simponi in patients with rheumatoid arthritis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.